NATCO Pharma Management
Management criteria checks 1/4
NATCO Pharma's CEO is Rajeev Nannapaneni, appointed in Jun 2012, has a tenure of 12.92 years. directly owns 0.6% of the company’s shares, worth ₹945.74M. The average tenure of the management team and the board of directors is 6.2 years and 1.1 years respectively.
Key information
Rajeev Nannapaneni
Chief executive officer
₹98.7m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 12.9yrs |
| CEO ownership | 0.6% |
| Management average tenure | 6.2yrs |
| Board average tenure | 1.1yrs |
Recent management updates
Recent updates
There's No Escaping NATCO Pharma Limited's (NSE:NATCOPHARM) Muted Earnings
May 22
Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Mar 24Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Mar 09Analysts Are More Bearish On NATCO Pharma Limited (NSE:NATCOPHARM) Than They Used To Be
Feb 19NATCO Pharma Limited (NSE:NATCOPHARM) Not Doing Enough For Some Investors As Its Shares Slump 30%
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Just Recorded An Earnings Miss And Analysts Are Updating Their Numbers
Feb 16
Future Revenue Will Decline As Competition Erodes Revlimid Pricing And R&D Costs Compress Margins
Uncertainty in pricing and revenue from Revlimid could impact net margins and limit R&D expenditure.Investors Aren't Buying NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings
Dec 23Is NATCO Pharma (NSE:NATCOPHARM) Using Too Much Debt?
Dec 08NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50
Nov 18Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Nov 15We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease
Oct 13NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market
Aug 13If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity
Jul 15NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly
Jun 30NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20CEO
Rajeev Nannapaneni (47 yo)
Sri Rajeev Nannapaneni serves as Chief Executive Officer at NATCO Pharma Limited since April 1, 2022 and also served as Vice Chairman since June 1, 2012 until April 1, 2022 and serves as its Vice Chairman...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Chairman | 43.7yrs | ₹100.77m | 8.9% ₹ 14.0b | |
| CEO & Vice Chairman | 12.9yrs | ₹98.67m | 0.60% ₹ 945.7m | |
| Chief Financial Officer | 9.3yrs | ₹13.36m | no data | |
| President of Technical Affairs & Whole Time Director | no data | ₹33.69m | 0.0030% ₹ 4.7m | |
| Company Secretary & Compliance Officer | 3.1yrs | ₹2.61m | no data | |
| Executive VP of Corporate Engineering Services & Whole Time Director | no data | ₹20.16m | 0.023% ₹ 36.1m | |
| VP & Head of Operations | no data | no data | no data | |
| Executive Vice President of Corporate Affairs | no data | no data | no data | |
| Vice President of Marketing & Sales - Domestic | 1.3yrs | no data | no data | |
| Senior Vice President of HR & Organisational Development | no data | no data | 0.0062% ₹ 9.7m | |
| Executive Vice President of R&D | 31.1yrs | no data | 0.025% ₹ 38.7m | |
| Senior Vice President of Demand & Supply Planning | no data | no data | no data |
Experienced Management: NATCOPHARM's management team is seasoned and experienced (6.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Chairman | 43.7yrs | ₹100.77m | 8.9% ₹ 14.0b | |
| CEO & Vice Chairman | 19.5yrs | ₹98.67m | 0.60% ₹ 945.7m | |
| President of Technical Affairs & Whole Time Director | 10.3yrs | ₹33.69m | 0.0030% ₹ 4.7m | |
| Executive VP of Corporate Engineering Services & Whole Time Director | 10.5yrs | ₹20.16m | 0.023% ₹ 36.1m | |
| Independent Director | 1.1yrs | no data | no data | |
| Independent Director | 1.1yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
Experienced Board: NATCOPHARM's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 11:53 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NATCO Pharma Limited is covered by 29 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Bhasin | Ambit Capital |
| Prashant Nair | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |